Central Precocious Puberty: Treatment with Triptorelin 11.25 mg

Table 1

Clinical data at the beginning of GnRH analog treatment (M0) and after 12 months of quarterly triptorelin 11.25 mg (M12).

	M0	M12
Bone age, years	9.8±1.2	10.7±1.1
Height, cm	132.7±7.8	139.1±8.6^∘
Height, SDS*	−0.4±1.3	−0.3±0.9
Growth velocity, cm/year	11.0±4.9	4.9±2.1^∘∘
Predicted adult height, cm	156.3±9.6	160.8±6.5
Predicted adult Height, SDS	−0.7±1.5	−0.2±1.1
Body mass index, kg/m^2	18.0±2.5	18.6±2.4
Body mass index, SDS	2.8±2.7	2.7±2.0
Midparental height, cm	161.0±4.5
Midparental height, SDS	−0.2±0.8

*SDS for bone age; ^∘𝑃<0.02 versus M0; ^∘∘𝑃<0.001 versus M0.